Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

67.77 -0.43 (-0.63%)
Streaming Delayed Price Updated: 12:16 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
81 82 Next >
Ozempic-Maker Novo Nordisk Reveals Patients Stay On Wegovy Weight-Loss Drug For 6 Months Due To Low Availability
Via Benzinga
Novo Nordisk Slumps On Second-Quarter Miss, Light Ozempic, Wegovy Sales
The company, however, hiked its sales outlook for the year. 
Via Investor's Business Daily
NVO Stock Earnings: Novo Nordisk Misses EPS, Misses Revenue for Q2 2024
NVO stock results show that Novo Nordisk missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy. 
Via The Motley Fool
Novo Nordisk Tumbles 3% In Wednesday Premarket: What's Causing 'Miracle' Weight Loss Drug Ozempic Maker's Stock Slide?
The dip in Novo Nordisk's shares comes despite deep-pocketed investors were adopting a bullish approach. 
Via Benzinga
Novo Nordisk Unusual Options Activity For August 06
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
Via Benzinga
Smart Money Is Betting Big In NVO Options
Via Benzinga
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly's Zepbound and Novo Nordisk's Wegovy face supply shortages, influencing doctors' prescribing habits. Both companies are investing heavily to meet demand in the lucrative U.S. market. 
Via Benzinga
After Ozempic And Botox, Hollywood Is Going Gaga Over This New Anti-Aging Supplement
This trend is gaining momentum although its effectiveness is yet to be determined. 
Via Benzinga
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market. 
Via The Motley Fool
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Psychologists warn of increased eating disorders linked to popular GLP-1 weight loss drugs like Wegovy and Zepbound. Experts urge better screening and research to address potential risks. 
Via Benzinga
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
Hims & Hers stock has been surging since May, but has its valuation gotten too rich? 
Via The Motley Fool
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users. 
Via Investor's Business Daily
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The innovative biotech is looking for its next blockbuster. 
Via The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
Why Eli Lilly Stock Trounced the Market on Thursday
What's good for Zepbound is good for the company, it seems. 
Via The Motley Fool
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Anti-obesity therapeutics are all the rage and for good reason. Investors seeking to profit should consider these weight loss stocks. 
Via InvestorPlace
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth. 
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals. 
Via InvestorPlace
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
FDA reports hospitalizations due to overdoses from compounded semaglutide products. Patients and health care providers miscalculate doses, leading to serious adverse events. The FDA advises proper... 
Via Benzinga
Exposures Product Safety
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Liraglutide shows promise in slowing cognitive decline in Alzheimer's patients, reducing brain volume loss and offering neuroprotective benefits, according to a Phase 2b clinical trial presented at... 
Via Benzinga
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
A study finds smokers with diabetes on Ozempic have fewer smoking-related medical interactions and interventions compared to those on other diabetes drugs. Research suggests potential for semaglutide... 
Via Benzinga
NYSE:NVO stands out as a growth opportunity that won't break the bank.
Investors should take note ofNOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced. 
Via Chartmill
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. 
Via The Motley Fool
3 Overlooked Stocks Poised for a Breakout Very Soon
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio. 
Via InvestorPlace
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.